Whitehawk Q2 net loss $52.6M; cash $177.2M, runway to 2028

Whitehawk Therapeutics, Inc.

2025-Q2 EPS reported $0.37 vs consensus $0.50 ▼ miss (-26.5%)

Net loss of $52.6M vs $14.6M Q2 2024; includes $38M upfront payment under Wuxi ADC deal.
Cash, equivalents & short-term investments $177.2M at June 30, 2025 (vs $47.2M Dec 31, 2024).
IND filings on track: HWK-007 and HWK-016 by year-end 2025; HWK-206 by mid-2026.
Cash anticipated to fund operations into 2028, enabling initial clinical data readouts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.